Corporate

[Corporate] 
[Academic
[Prof. Activities
[Education
[Patents
[Publications
[NonProfessional] 

 

 

 1997-1999  

LJL BioSystems, Inc., Sunnyvale, CA

(Fluorometric High-Throughput Screening for Drug Discovery)

Sr. Dir., Mol. & Cell Applications ® V.P. Research

 

    Started LJL's reagent R&D and manufacturing effort, directing development and manufacturing of LJL's first reagent product (TKX™ fluorescence-polarization assay for tyrosine-kinase activity).

    Directed research program to design new long-lifetime fluorescent labels for energy-transfer and polarization applications (supervised synthetic organic chemists).

    Co-directed FLARe™ program to produce first fluorometric detection system based on frequency-domain fluorescence-lifetime assays in microplates (goal:  increased robustness of assays for high-throughput screening).

    Contributed significantly to design of Analyst™ and Acquest™ microplate detection systems (internal consulting with engineers on performance requirements and detection methods).

    Principal technical spokesperson for LJL, speaking at six conferences and many customer sites.

 

1987-1997:

Molecular Devices Corporation, Sunnyvale, CA

(Cellular Assays in Drug Discovery; Bioanalytical Application of Silicon Chips)

Research Scientist ® Associate Technical Director

 

    Directed applications development for FLIPR™ (Fluorometric Imaging Plate Reader) system for fluorometric functional kinetic assays on living cells.

    Performed and directed much of the initial research defining microphysiometry, the connection between cell physiology and extracellular acidification rate using proprietary silicon-based biosensor. 

    Co-inventor on the fundamental patent on microphysiometry and co-author of two papers in Science (one a cover article).

    Principal role in establishing microphysiometry as a pharmacological tool for detecting receptor activation. 

    Instituted and managed central cell-culture facility. 

    Directed recombinant expression of receptors and signal-transduction proteins. 

    Directed biological component of development of high-performance microfabricated/microfluidic microphysiometer, suitable for drug screening. 

    Directed one third of $12.4M, 4-year DARPA contract; administered entire contract in its final phases. 

     

 

[Home][Consulting][Short Courses][Personal Info][Contact Info]